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The African Comprehensive HIV/AIDS Partnerships-A
New Role for Multinational Corporations in Global Health
Policy
Linda M. Distlerath, Ph.D.* and Guy Macdonald~t
Merck & Co., Inc.
MERCK'S COMMITMENT TO GLOBAL HEALTH
While some scholars have argued that companies should only serve the
immediate financial goals of their stockholders, Merck and Co., Inc., one
of the world's leading research-based pharmaceutical firms, has long taken
a different position when it comes to alleviating the impact of disease in
the developing world. All major pharmaceutical firms have an obligation to
offer assistance when social, political, and economic conditions make it
impossible for patients to receive life-saving therapies. On a practical level,
there are clearly constraints: Merck's primary role in global health is to
discover, produce and distribute innovative drugs and vaccines to address
unmet medical needs worldwide. Merck and other pharmaceutical firms
must have the resources - including investor support - necessary to
continue performing that role. Merck's research programs to develop safe,
effective vaccines for HIV/AIDS, rotavirus, and human papillomavirus
attest to its commitment to address diseases of global magnitude for all
people regardless of their economic situation. However, Merck recognizes
that bringing new drugs and vaccines through regulatory approval and into
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member of the African Comprehensive HIV/AIDS Partnerships (ACHAP) Board of
Directors.
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Mr. Macdonald has taken a position as Executive Vice President of Operations with Idenix
Pharmaceuticals.
t Merck & Co., Inc., operates in most countries outside the United States as Merck
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the marketplace does not necessarily result in people having access to life-
prolonging medicines, especially in those regions of the world where the
health care infrastructure is inadequate and poverty overwhelming. In
these regions, Merck and other large producers should help remove the
barriers that stand between patients and the therapies they need.
Multinational pharmaceutical companies thus share with the
governments of the developed nations and international institutions a
complex social obligation. In meeting those obligations, Merck invests not
only in the expected - with a research and development budget for 2003
exceeding three billion dollars-but also in the social goods that enable
access to medicines and health care around the world. Improving global
health by investing in human, physical and intellectual capital saves lives
and can also stimulate the economic development necessary to pull
communities and countries out of poverty. This in turn shapes a more
favorable environment for multinational companies like Merck to continue
pursuit of new drugs and vaccines against diseases yet unconquered. In the
long term, the company believes, these social investments serve the best
interests of its stockholders as well as those of people living in developing
societies. This strategy explains Merck's partnership with the government
of Botswana and the Bill & Melinda Gates Foundation-the African
Comprehensive HIV/AIDS Partnerships (ACHAP)-an ongoing effort to
combat that nation's leading health crisis.
THE AFRICAN COMPREHENSIVE HIV/AIDS PARTNERSHIPS
Merck's AIDS research program has spanned more than fifteen years,
yielding two antiretroviral drugs and a promising HIV/AIDS experimental
vaccine in early human clinical trials.' Realizing the challenges in access to
HIV/AIDS medicines in the developing world-especially in sub-Saharan
Africa-Merck has entered into numerous partnerships with governments,
international organizations, foundations, other corporations and non-
governmental organizations (NGOs) as it attempts to deal effectively with
the global HIV/AIDS pandemic.
It was in this context that Merck decided to launch a comprehensive
program of HIV/AIDS prevention, care, treatment and support in one
1. Louis GAIAMBOS &JANE ELIOT SEWELL, CONFRONTING AIDS: SCIENCE AND BUSINESS
CROSS A UNIQUE FRONTIER (1999); see also Press Release, Merck & Co., Merck's
Investigational HIV Vaccine Candidate To Be Studied In Collaborative Clinical Trial To
Begin in 18 Cities Around the World (Sept. 19, 2003),
http://www.merck.com/newsroom/press-releases/research-anddevelopment/2003_0919
.html (last visited Dec. 10, 2003).
IV:I1 (2004)
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country in sub-Saharan Africa. The enormity of the pandemic seemed to
be creating institutional and political gridlock.' Meanwhile, people were
dying prematurely and HIV infections were continuing to spread. Merck
set out to create a pilot program, which-if successful-could provide
guidelines for other developing nations, for international organizations,
for foundations, and for the governments of developed countries that
ultimately would have to bear the tremendous cost of any comprehensive
plan. To be successful, this program had to be implemented in
cooperation with an African government that had the political will to
mount an integrated fight against HIV/AIDS. If these conditions were met,
an additional bolus-type infusion of funding, drugs and technical
assistance could have both an immediate and long-lasting impact.
3
Merck, which was willing to commit $50 million toward such an effort
through the Merck Company Foundation, sought other potential funding
partners from the business, public sector and foundation world. Most
companies and other institutions were skeptical of a partnership focused
on just one country, but the Bill & Melinda Gates Foundation was willing
to invest in this still undefined program. By late 1999, the Gates
Foundation was already committed to expanding its global health
programs, including those in HIV/AIDS, and it brought to the partnership
strong financial support and substantial expertise.4 Together, the Gates
Foundation and Merck set out to develop a program that would encourage
others in the pharmaceutical industry, in governments, and in foundations
to act swiftly to stem this deepening crisis.
The two partners set out to focus these resources on one country,
something that neither international organizations nor the governments of
2. HANNAH E. KETTLER, NARROWING THE GAP BETWEEN PROVISION AND NEED FOR
MEDICINES IN DEVELOPING COUNTRIES (2000); MDECINS SANS FRONTIERES, FROM DURBAN TO
BARCELONA: OVERCOMING THE TREATMENT DEFICIT (2002), available at
http://www.doctorswithoutborders.org/publications/reports/2002/fdtb-O7-2002.pdf (last
visited Dec. 10, 2003); UNAIDS & HARVARD SCH. OF PUB. HEALTH, LEVEL AND FLOW OF
NATIONAL AND INTERNATIONAL RESOURCES FOR THE RESPONSE TO HIV/AIDS, 1996-1997
(1999). For a discussion of the delay in United States assistance, see Jeanne Cummings,
African Aid SlowedAmid U.S. Wrangling, WALL ST.J.,July 11, 2003, at A4.
3. See, e.g., UNAIDS, ACCELERATING ACTION AGAINST AIDS IN AFRICA (2003) (discussing
the importance of leadership in Botswana).
4. Press Release, Bill & Melinda Gates Foundation, The Bill & Melinda Gates
Foundation, Merck & Co., Inc., and the Republic of Botswana Launch New HIV Initiative
(July 10, 2002),
http://www.gatesfoundation.org/GlobalHealth/HVAIDSTB/HIVAIDS/Announcements/
Announce-243.htm (last visited Dec.22, 2003).
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donor nations could easily do based on their chartered mandates or
traditional modes of international aid. After reviewing the impact of
HIV/AIDS in various sub-Saharan countries, the level of health care
infrastructure and demonstration of political will and government
commitment, Gates and Merck realized that one country stood out:
Botswana. Politically stable and known for good governance, Botswana had
the important advantage of strong leadership by President Festus Mogae,
who was deeply committed to fighting the epidemic ravaging his country.
With 35.4% of the adult population infected, Botswana has the world's
highest reported HIV rate. A small country with a record of strong
economic growth during its first 35 years of independence, Botswana had
not yet felt the full impact of the epidemic, but HIV/AIDS clearly was
threatening its very existence."
After meeting with representatives of Merck and the Gates Foundation
in July 2000, President Mogae agreed to launch the African
Comprehensive HIV/AIDS Partnerships, a public-private collaboration
between the Government of Botswana, Merck, and the Bill & Melinda





THE DEVELOPMENT, IMPLEMENTATION AND IMPACT OF ACHAP
To be successful, the new program needed substantial resources and a
commitment to transparency and accountability. Merck and the Bill &
Melinda Gates Foundation each dedicated fifty million dollars to ACHAP
over a five-year period. In addition, Merck is donating its HIV medicines to
the Government of Botswana's antiretroviral (ARV) therapy program and
is assisting with the development and management of the ACH-AP
organization. A board of directors, which has primary responsibility for
transparency and accountability, oversees these funds: authorizing budgets,
approving proposals and providing direction on strategy and operations.
Dr. Donald de Korte, former managing director of Merck's subsidiary in
South Africa, headed up the operation in Botswana, managing a core team
of twenty, complemented by consultants seconded to ministries and
5. NATIONAL AIDS COORDINATING AGENCY, STATUS OF THE 2002 NATIONAL RESPONSE TO
THE UNGASS DECLARATION OF COMMITMENT ON HIV/AIDS: GOVERNMENT OF BOTSWANA
COUNTRY REPORT ( 2003), available at
http://www.naca.gov.bw/documents/REPORT%2012%2Mar%2031%202003%201711%2
OHours.pdf (last visited Dec. 22, 2003) [hereinafter "2002 NATIONAL RESPONSE TO THE
UNGASS DECLARATION OF COMMITMENT ON HIV/AIDS"].
6. Interview with Festus Mogae, President, Botswana (July 2000).
IV:] (2004)
4
Yale Journal of Health Policy, Law, and Ethics, Vol. 4 [2004], Iss. 1, Art. 9
https://digitalcommons.law.yale.edu/yjhple/vol4/iss1/9
CASE STUDY-DISTLERATH & MACDONALD
7
sectors.
Relations between the two United States partners and the government
of Botswana were crucial to success. Under pressure to act quickly and
decisively, there were disagreements about what should be done and how it
should be accomplished-especially in the early development of the
formal operational relationships between the partners. In the pressure
cooker of the pandemic, cultural differences emerged over efficiency, over
changes that were needed in relatively rigid social systems and methods of
delivering services, and over operational paradigms that had political but
not medical saliency. Breaking down functional boundaries seemed
natural to planners attuned to corporate reengineering and fast-track
mechanisms, but not always to political leaders sensitive to local patterns of
behavior and status. 8
With some grinding and a great deal of good will, however, these
problems were turned into relatively minor impediments in the overall
progress of ACHAP. There was from the beginning a solid consensus about
the nature of the crisis and the need to move forward as quickly as due
diligence, available personnel and government procedures allowed. As a
result, during its first three years, ACHAP was able to keep a tight focus on
three specific objectives: 1) building institutional capacity; 2)
strengthening the health care system, including prevention and treatment
services; and 3) creating and expanding community initiatives for
HIV/AIDS education and the care and support for people living with the
infection.
ACHAP-SUPPORTED PROGRAMS IN BOTSWANA
ACH-AP's effort in capacity-building includes programs expanding and
fortifying human resources and those providing technical advice and
support. ACHAP assisted in the elaboration of Botswana's national
HIV/AIDS strategy, including the development of a national monitoring
and evaluation system and the provision of a needs assessment toolkit that
will guide future HIV/AIDS interventions at the district level. ACHAP has
trained more than 500 government, NGO and other key players on project
7. For details on the organization and direction of ACHAP, see http://www.achap.org.
See also Tracey Naledi, The African Comprehensive HIV/AIDS Partnerships: A Model for
Allocating Resources in the Developing World (May 2003) (unpublished manuscript, on
file with ACHAP).
8. See Naledi, supra note 7. See also NATIONAL AIDS COORDINATING AGENCY, THE
NATIONAL HIV/AIDS STRATEGIC FRAMEWORK 2003-2009 (2003); 2002 NATIONAL RESPONSE TO
THE UNGASS DECLARATION OF COMMITMENT ON HIV/AIDS, supra note 5.
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development, monitoring and evaluation, leadership skills and proposal
development, media training and computer skills, Many of these areas of
capacity-building are not HIV/AIDS specific, but they provide some of the
fundamental underpinnings to support Botswana's national strategic
framework for HIV/AIDS.
In the technical area, HIV/AIDS training programs for care and
treatment-both in the classroom through the Harvard AIDS Institute and
in the clinic with HIV experts from hospitals in Europe and the United
States-have been provided to over 1200 health care workers, with the aim
of reaching all Botswana's medical personnel by the end of 2003. A
number of other ACHAP programs focus on skill-building for HIV/AIDS
education as a means to increase awareness and knowledge and to de-
stigmatize the disease. For example, a distance-learning initiative
conducted in collaboration with the UN, Botswana TV and the Botswana
Ministry of Education is reaching teachers in more than 400 schools.9
Key A CHAP interventions within the national strategic framework include:
" A program establishing the relationship between alcohol abuse
and HIV transmission and a related effort aimed at the
development of behavior change communication through
market segmentation;
* A program introducing routine and diagnostic HV testing to
increase rapidly the number of people knowing their status;
* Education programs on condoms to dispel misconceptions
about HIV/AIDS; a project to install more than 10,500
dispensers providing free condoms throughout the country;
* A program providing small grants to fund community-based
initiatives;
* Support for the construction of health resource centers at
hospitals and daycare facilities for orphans;
* Programs involving an array of support and counseling
services, including faith-based services, pre-and post-test
counseling, leadership development, the establishment of
district responses to mobility, and interventions emphasizing
youth prevention and blood safety. l
9. Teacher Capacity-Building Programme, African Comprehensive H1V/AIDS
Partnerships, at http://www.achap.org/TCBP.htm (last visited Nov. 10, 2003).
10. GOVERNMENT OF BOTSWANA, MINISTRY OF HEALTH, DAWN: CHALLENGES AND LEARNINGS
OF ARV IMPLEMENTATION IN BOTSWANA (2003); African Comprehensive HIV/AIDS
Partnerships, at-http://www.achap.org (last visited Dec. 10, 2003).
IV:l1 (2004)
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Several months after the initiation of ACHAP, President Mogae
decided to offer antiretroviral (ARV) treatment to all those in Botswana for
whom it was clinically indicated. To support this bold effort, ACHAP
secured the pro bono services of McKinsey & Company, a management
consultant firm, to work with the government in the planning and
development of a government-run ARV program. Since the program's
launch in January 2002, ACHAP has continued to support this crucial
initiative with technical, managerial, and human resources, including
resources to increase the capacity of laboratories nationwide, to install an
IT-based patient management system, to train teams of health care workers
in the hospitals and clinics, to build drug storage facilities and clinics, and
to launch an aggressive information, education, and communications
campaign. This style of bottom-up and top-down infrastructure
development has been critical to the success of the ARV plan.
The program, which is called Masa ("dawn" in Setswana), had enrolled
more than 12,000 patients by September 2003. Although most of the
Batswana still do not know their HIV status and the cultural stigma of
infection continues to be a serious problem, Masa is already the largest
government-sponsored ARV treatment program in Africa. Adherence to
the drug plan has been greater than 85%, and 85% of the patients on the
therapy have achieved complete viral suppression after six months."
Rapid expansion of the program is now underway, with more sites for
treatment under development.1 2 Meanwhile, new initiatives will strengthen
blood safety practices, develop additional disease prevention programs for
highly mobile populations, address the high risk practices of traditional
healers and integrate them into mainstream prevention, treatment and
care efforts, and mobilize private firms in Botswana to provide HIV/AIDS
services for their employees and families, as well as for the communities
where they conduct business.
ACHAP: BOTSWANA'S LESSONS
ACHAP has been successful to date in large part because it is fully
integrated with the government's strategy, because it is able to leverage the
benefits of the private sector to support public health aims, and because
the development of its strategy is locally driven. ACHAP is enhancing local
capacity through the transfer of managerial, leadership and technical skills
11. Ernest Darkoh, The Masa Antiretroviral Therapy Program in Botswana,
Presentation to the Bill and Melinda Gates Foundation (September 24, 2003).
12. See id.
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to Botswana's citizens. By being fully integrated, it is able to build on
existing systems and structures. By developing specific, realistic goals,
ACHAP is fostering an environment characterized by individual and
institutional accountability and is optimizing resource allocation. The
struggle to develop an effective infrastructure, to build the requisite
human resource capacity, and to transform deep-set cultural values will go
on for many years. But already, ACHAP and the Government of Botswana
have made significant progress in developing a comprehensive and
sustained national response to HIV/AIDS.
The ACHAP experience demonstrates the importance of
implementing reforms in one particular country and in every part of that
country, on the regional and the local level. All medicine, like politics, is
ultimately local. ACHAP built essential relationships with crucial partners
and stakeholders, those with responsibilities and accountabilities within
the country. With some effort, private-sector effectiveness has been
achieved in public organizations. As this experience indicates, the
international, the national, and the local elements can be aligned. This can
be done despite inadequate numbers of qualified staff, high attrition rates
due to illness and death, underdeveloped monitoring and evaluation
expertise, and an insufficient infrastructure to accommodate the large
number of patients that need treatment.
What are the key principles that might be applicable to such
partnerships in other countries? We feel there are five attributes that
warrant consideration:
* ACHAP is an independent yet fully engaged entity solely
devoted to supporting a national response to HIV/AIDS
through the timely development, implementation, management
and evaluation of programs. ACHAP has a tight focus and has
operated with specific deadlines and realistic goals, full
accountability, and a high degree of transparency.
* ACHAP has been able to leverage private sector management
and foundation resources in a government-led planning and
implementation process. This is a true partnership, not a lop-
sided alliance dominated by one or more of the participants.
ACHAP is a de facto, as well as a dejure, partnership.
* ACHAP is fully integrated with government processes and
procedures and has never attempted to operate independently
of the government of Botswana. This is perhaps easier to
accomplish with a public-private partnership than it would be
with a government-to-government program, with agency rules,
legislatures, and executives on both sides of the program. Tight
IV:I1 (2004)
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integration means that ACHAP's desire to be fast and efficient
must be tempered-and occasionally frustrated-by the
government's bureaucracy. Still, there is a lesson here for the
developed nations that will perforce pick up the programs that
ACHAP has helped launch.
* ACHAP has been able to help the government of Botswana
identify, acquire, and employ the resources and technical
expertise (sometimes through management consultants)
needed to build training programs and the institutional and
human capacity that the country lacked. The United States
partners' global contacts and experience with health-related
programs were critical to these initial infrastructure- and
capacity-building activities.
* ACHAP's determination to be efficient and results-driven has
enabled the partnership to build both individual and
institutional accountability in its complex, locally based
program. Good financial and organizational management,
honed in the foundation and corporate worlds, enabled this
partnership to achieve substantial, measurable results within
three years.
The ultimate measure of the success of ACHAP will be the extent to
which the goals of the Government of Botswana can be achieved:
reduction in the incidence of HIV and alleviation of the burden of
HIV/AIDS on the people, their communities and their country. It will be
several more years before this effort can be fully evaluated. In the
meantime, the ACHA-P partners-Merck, the Gates Foundation, and the
government of Botswana-are committed to sharing their experiences so
that others engaged in the struggle against HIV/AIDS in the developing
world can learn from the work of this unique public-private partnership.
The success to date suggests that there truly is hope for all those in sub-
Saharan Africa infected and affected by HIV.
9
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